COVID-19 疫苗接种对使用连续血糖监测的 1 型糖尿病儿童和青少年血糖控制的影响。
The impact of COVID-19 vaccination on glycaemic control in children and adolescents with type 1 diabetes mellitus on continuous glucose monitoring.
机构信息
1st Paediatric Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Ippokratio General Hospital, 49 Konstantinoupoleosstr, 54642, Thessaloniki, Greece.
出版信息
Acta Diabetol. 2022 Dec;59(12):1609-1614. doi: 10.1007/s00592-022-01968-y. Epub 2022 Sep 7.
AIMS
To investigate the impact of SARS-COV-2 vaccination on the glycaemic control in children and adolescents with T1DM wearing continuous glucose monitoring (CGM).
METHODS
Caregivers of children and adolescents with T1DM were questioned regarding SARS-CoV-2 vaccination during their regular visits at the Pediatric Diabetes Outpatient Clinic. Data regarding Time in Range (TIR) (glucose levels: 70-180 mg/dl) 7 days prior and 7 days after a vaccination dose were collected in patients wearing CGM and data regarding insulin daily doses were also obtained for the insulin pump users.
RESULTS
From a total of 135 patients eligible for SARS-CoV-2 vaccination, 70 (51.9%) children (37 boys, 52.9%) were vaccinated with at least one dose. Seven patients received only one dose, whereas two children received a third booster shot. No statistically significant difference was observed in either TIR (64.19% post vs. 65.53% pre, p = 0.158) or total daily insulin dose (40.08 U/day post vs. 39.32 U/day pre, p = 0,282). Additionally, in ten patients on Hybrid Closed-Loop System the percentage of the automated insulin boluses given post-vaccination was not statistically significant different compared to the boluses given pre-vaccination (15.80% vs. 16.90%, p = 0,491).
CONCLUSIONS
Vaccination against SARS-CoV-2 in children and adolescents with T1DM is safe and is not associated with immediate glucose imbalance.
目的
研究 SARS-CoV-2 疫苗接种对佩戴连续血糖监测仪（CGM）的 1 型糖尿病（T1DM）患儿血糖控制的影响。
方法
在儿科糖尿病门诊就诊期间，询问 T1DM 患儿的照顾者是否接种了 SARS-CoV-2 疫苗。在佩戴 CGM 的患者中，收集疫苗接种剂量前 7 天和后 7 天的时间在目标范围内（TIR）（血糖水平：70-180mg/dl）数据，并且还为胰岛素泵使用者获得了胰岛素每日剂量的数据。
结果
共有 135 名符合 SARS-CoV-2 疫苗接种条件的患者，其中 70 名（51.9%）儿童（37 名男孩，52.9%）至少接种了一剂疫苗。7 名患者仅接种了一剂，而 2 名儿童接种了第三剂加强针。TIR（接种后 64.19% vs. 接种前 65.53%，p=0.158）或总日胰岛素剂量（接种后 40.08U/天 vs. 接种前 39.32U/天，p=0.282）均无统计学差异。此外，在 10 名接受混合闭环系统治疗的患者中，接种疫苗后自动给予胰岛素剂量的百分比与接种疫苗前相比没有统计学差异（15.80% vs. 16.90%，p=0.491）。
结论
在 T1DM 患儿中接种 SARS-CoV-2 疫苗是安全的，并且不会立即导致血糖失衡。
Zotero 插件